45,532 results match your criteria Hodgkin Disease


Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkin's lymphoma.

Ann Hematol 2019 Apr 17. Epub 2019 Apr 17.

Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Bari, Italy.

Thanks to the increased number of young survivors of Hodgkin's lymphoma (HL), management of the pregnancies of women who have a history of exposure to chemotherapies and radiation therapy is becoming increasingly common. Many patients and clinicians are worried that pregnancy after the diagnosis of HL may increase the risk of relapse, despite a lack of empirical evidence to support such concerns. In the present study, we included 89 women diagnosed with HL between 2006 and 2015 under the age of 50 years, who were in complete remission and alive without relapse > 1 year after treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03684-0DOI Listing

Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Acta Oncol 2019 Apr 17:1-10. Epub 2019 Apr 17.

a Institute of Neurology , Medical University of Vienna , Vienna , Austria.

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups.

Material And Methods: Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1599137DOI Listing

Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.

Support Care Cancer 2019 Apr 15. Epub 2019 Apr 15.

Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.

Purpose: Limited information is available regarding elderly patients experiencing febrile neutropenia (FN). This study evaluated FN-related care among elderly cancer patients who received high/intermediate FN-risk chemotherapy and experienced ≥ 1 FN episodes.

Methods: We used Medicare data to identify patients aged ≥ 66 years who initiated high/intermediate FN-risk chemotherapy between 1 January 2008 and 31 August 2015 to treat breast cancer (BC), lung cancer (LC), or non-Hodgkin lymphoma (NHL) and had ≥ 1 FN episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04795-0DOI Listing

Postchemotherapy Histiocyte-Rich Pseudotumor of the Spleen Simulating Residual Disease in a Patient With Non-Hodgkin Lymphoma on FDG PET/CT.

Clin Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

the Department of Hematology, Soroka University Medical Center, Beer-Sheva, Israel. Affiliated to Ben Gurion University of the Negev, Faculty of Health Sciences.

A 64-year-old man was treated with multiagent chemotherapy owing to high-grade non-Hodgkin lymphoma presenting as a bulky disease involving the spleen. Interim and posttreatment sequential FDG PET/CT scans revealed a residual splenic mass showing markedly intense FDG uptake suspected of a residual viable lymphoma. To definitely decide about the appropriate treatment, a laparoscopic splenectomy was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002568DOI Listing

Extranasal extranodal NK/T cell lymphoma: A post-transplantation lymphoproliferative disease.

Int Wound J 2019 Apr 14. Epub 2019 Apr 14.

Department of Dermatology, Medical Faculty, Ege University, Izmir, Turkey.

Extranodal NK/T cell lymphoma (ENKTL) is a rare form of non-Hodgkin lymphoma. It mostly occurs in the upper respiratory tract. Cutaneous involvement can be seen among the extranasal ENKTLs. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/iwj.13126
Publisher Site
http://dx.doi.org/10.1111/iwj.13126DOI Listing
April 2019
7 Reads

Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults.

J Am Acad Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Assistance Publique-Hôpitaux de Paris, Département de Dermatologie, Hôpital Saint-Louis, Paris, France; Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Electronic address:

Background: Paraneoplastic pemphigus (PNP) occurs more often in patients with hematologic malignancies (HMs) than in patients with solid cancer. Lung bronchiolitis obliterans (BO) is a severe complication of PNP.

Objective: To determine the precise clinical and biologic features of HM-associated PNP and identify factors associated with mortality and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.043DOI Listing

Non-Hodgkin's lymphoma with extensive emperipolesis mimicking Rosai-Dorfman disease: A rare case report.

Indian J Pathol Microbiol 2019 Apr-Jun;62(2):319-322

Department of Pathology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India.

Emperipolesis is the hallmark finding for Rosai-Dorfman disease. Till now many studies in literatures have shown emperipolesis as a finding in other benign as well as malignant conditions. Very few cases of malignant lymphoma have this phenomenon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_409_18DOI Listing
April 2019
1 Read

Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.

BMC Cancer 2019 Apr 11;19(1):338. Epub 2019 Apr 11.

Health Economics Unit, Department of Clinical Science (Malmö), Lund University, Lund, Sweden.

Background: Prognoses of most adult Hodgkin lymphoma (HL) patients are excellent; most of them can achieve permanent remission that can be considered cured. However, many are under-treated or over-treated by standard modern therapies. An accurate determination of prognosis may allow clinicians to design personalised treatment according to individual risk of disease progression and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5552-1DOI Listing
April 2019
2 Reads

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.

Exp Hematol Oncol 2019 28;8. Epub 2019 Mar 28.

1Institute for Advanced Biosciences, Université Grenoble Alpes, INSERM 1209, UMR CNRS 5309, Grenoble, France.

Background: Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with other treatments remains to be thoroughly documented. Here we report the case of a 33-year-old male with classical Hodgkin lymphoma who was successfully treated for lymphoma but experienced serious and eventually fatal multisystem organ failure following nivolumab administration and allogeneic stem cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-019-0132-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437980PMC
March 2019
1 Read

Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis.

Am J Pathol 2019 Apr 4. Epub 2019 Apr 4.

Baylor Scott & White Digestive Disease Research Center, Temple, Texas; Division of Research, Central Texas Veterans Health Care System, Temple, Texas. Electronic address:

Hepatitis C virus (HCV) infection is a global public health problem because it is a main cause of liver cirrhosis and hepatocellular carcinoma. This human oncogenic virus is also associated with the development of non-Hodgkin lymphoma and cholangiocarcinoma (CCA). The association between HCV infection and CCA has been examined in a number of epidemiologic studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2019.01.018DOI Listing
April 2019
4 Reads

Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients.

BMC Cancer 2019 Apr 5;19(1):316. Epub 2019 Apr 5.

Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and Uppsala University Hospital, Rudbeck Laboratory, C5, SE-75185, Uppsala, Sweden.

Background: Regulatory immune cells may modulate the lymphoma microenvironment and are of great interest due to the increasing prevalence of treatment with immunotherapies in lymphoma patients. The aim was to explore the composition of different immune regulatory cell subsets in the peripheral blood of newly diagnosed lymphoma patients in relation to treatment outcome.

Methods: Forty-three newly diagnosed patients with lymphoma were included in the study; 24 with high-grade B-cell lymphoma (HGBCL) and 19 with classical Hodgkin lymphoma (cHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5529-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449984PMC
April 2019
3 Reads

Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma: A Large Population-based Study Using the SEER Database.

Am J Clin Oncol 2019 Apr 3. Epub 2019 Apr 3.

Department of Hematology and Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

Introduction: Primary pancreatic lymphoma (PPL) is an extranodal manifestation of non-Hodgkin lymphoma originating in the pancreas, which constitutes <1% of all pancreatic neoplasms. Because of the rarity of the disease, most data on PPL are derived from case reports and small case series. To provide better insight into the epidemiology, treatment, and outcomes of these patients, we conducted an analysis of patients with PPL from the Surveillance, Epidemiology and End Results (SEER) database, which is presented in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000544DOI Listing
April 2019
2 Reads

Hepatic Manifestations of Lymphoproliferative Disorders.

Clin Liver Dis 2019 May 2;23(2):293-308. Epub 2019 Mar 2.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

Hepatic abnormalities in patients with lymphoproliferative disorders are common and can occur from direct infiltration by abnormal cells, bile duct obstruction, paraneoplastic syndrome, hemophagocytic syndrome, drug-induced liver injury, opportunistic infections, and reactivation of viral hepatitis. Hepatic involvement by lymphoma is often in association with systemic disease and rarely seen as a primary hepatic lymphoma. Vanishing bile duct syndrome is a well-known complication of Hodgkin disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cld.2018.12.010DOI Listing
May 2019
1 Read

Early chemotherapy de-escalation strategy in advanced-stage Hodgkin lymphoma patients with negative positron emission tomography scan after two escalated BEACOPP cycles.

Pol Arch Intern Med 2019 Apr 4. Epub 2019 Apr 4.

INTRODUCTION Escalated BEACOPP (escBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) significantly improves overall response rates (ORR) and prolongs progression-free survival (PFS) in advanced-stage Hodgkin lymphoma (HL) patients. However, 6-8 cycles of escBEACOPP are associated with increased acute toxicity and late complications. OBJECTIVES We aimed to determine the role of early positron emission tomography-computed tomography (PET-CT) response assessment in the de-escalation strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20452/pamw.14786DOI Listing
April 2019
1 Read

Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.

J Cutan Med Surg 2019 Apr 3:1203475419840629. Epub 2019 Apr 3.

1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. Mycosis fungoides (MF), the most common subtype, and the rarer Sézary syndrome (SS), are considered the classical forms of CTCL, which, because of a varying presentation and lack of genetic and immunophenotypical markers, can often have a delayed diagnosis. With skin-directed topical treatment being the mainstay of therapy in the early stages, there is an absence of long-term curative therapies for advanced disease. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1203475419840629
Publisher Site
http://dx.doi.org/10.1177/1203475419840629DOI Listing
April 2019
7 Reads

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Oncologist 2019 Apr 2. Epub 2019 Apr 2.

Institute of Hematology, University of Bologna, Bologna, Italy

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently available treatments. Lenalidomide is available in Italy for patients with rrDLBCL based on a local disposition of the Italian Drug Agency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0603DOI Listing
April 2019
7 Reads

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

JCI Insight 2019 Apr 2;5. Epub 2019 Apr 2.

Background: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on safety and efficacy of autologous CD19-targeted CAR T-cells for these patients; here we report safety and long-term follow-up of CAR T-cell therapy with or without conditioning chemotherapy for patients with R/R CLL and indolent B-cell non-Hodgkin lymphoma (B-NHL).

Methods: We conducted a phase 1 clinical trial investigating CD19-targeted CAR T-cells incorporating a CD28 costimulatory domain (19-28z). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.122627DOI Listing
April 2019
2 Reads

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Lancet Haematol 2019 Mar 29. Epub 2019 Mar 29.

US Oncology and Willamette Valley Cancer Institute, Springfield, OR, USA.

Background: Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 study was to compare rituximab plus pola (R-pola) or pina (R-pina) in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

Methods: In this phase 2 randomised study at 39 investigational sites in six countries, patients were randomly assigned (1:1), by use of a dynamic hierarchical randomisation scheme, to receive R-pola or R-pina (375 mg/m rituximab plus 2·4 mg/kg ADCs) every 21 days until disease progression or unacceptable toxicity up to 1 year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30026-2DOI Listing
March 2019
4 Reads

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy.

Cancers (Basel) 2019 Mar 25;11(3). Epub 2019 Mar 25.

Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine Chicago Illinois, Chicago, IL 60611, USA.

Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10⁻20% of patients with early stage disease and 30⁻40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/3/421
Publisher Site
http://dx.doi.org/10.3390/cancers11030421DOI Listing
March 2019
2 Reads

Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma.

Int Rev Immunol 2019 Mar 31:1-13. Epub 2019 Mar 31.

a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences , Tehran , Iran.

Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the aggressive or relapsed/refractory NHL subjects experience relapses following RIT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08830185.2019.1588266DOI Listing
March 2019
1 Read
4.103 Impact Factor

Unraveling Tumor Heterogeneity in an Apparently Monolithic Disease: BCL2 and Other Players in the Genetic Landscape of Nodal Follicular Lymphoma.

Front Med (Lausanne) 2019 15;6:44. Epub 2019 Mar 15.

Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Follicular lymphoma (FL) is the most common form of non-Hodgkin lymphoma in Western countries. Although traditionally considered a well-defined, easy to diagnose lymphoproliferative disorder, in the last few years it has become clear that it is in fact composed of many different clinicopathological entities, encompassing a variegated and complex genetic background. This has led to the inclusion of specific FL variants and separate entities in the latest update of the WHO classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2019.00044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428742PMC
March 2019
1 Read

Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma.

Front Microbiol 2019 15;10:475. Epub 2019 Mar 15.

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.

Polymorphisms in the immune response genes can contribute to clearance of hepatitis C virus (HCV) infection but also mediate liver inflammation and cancer pathogenesis. This study aimed to investigate the association of polymorphisms in PD-1 (PDCD1), IFNL3 (IL28B), and TLR2 immune related genes in chronic HCV patients with different hepatic and lymphoproliferative HCV-related diseases. Selected PDCD1, IFNL3, and TLR2 genes were tested by molecular approaches in 450 HCV-positive patients with increasing severity of underlying liver diseases [including chronic infection (CHC), cirrhosis and hepatocellular carcinoma (HCC)], in 238 HCV-positive patients with lymphoproliferative diseases [such as cryoglobulinemia and non-Hodgkin lymphoma (NHL)] and in 94 blood donors (BD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmicb.2019.00475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429030PMC
March 2019
1 Read
3.941 Impact Factor

Impact of acquisition count statistics reduction and SUV discretization on PET radiomic features in pediatric 18F-FDG-PET/MRI examinations.

Phys Med 2019 Mar 16;59:117-126. Epub 2019 Mar 16.

Medical Physics Department, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Purpose: The evaluation of features robustness with respect to acquisition and post-processing parameter changes is fundamental for the reliability of radiomics studies. The aim of this study was to investigate the sensitivity of PET radiomic features to acquisition statistics reduction and standardized-uptake-volume (SUV) discretization in PET/MRI pediatric examinations.

Methods: Twenty-seven lesions were detected from the analysis of twenty-one 18F-FDG-PET/MRI pediatric examinations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2019.03.005DOI Listing

Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2.

J Clin Immunol 2019 Mar 29. Epub 2019 Mar 29.

Department of Clinical Immunology and Allergy, Royal Melbourne Hospital, Parkville, VIC, 3052, Australia.

Common variable immunodeficiency is the most prevalent of the primary immunodeficiency diseases, yet its pathogenesis is largely poorly understood. Of the cases that are monogenic, many arise due to pathogenic variants in NFKB1 and NFKB2. Here, we report enteroviral encephalomyelitis as the cause of a fatal neurodegenerative condition in a patient with a novel heterozygous mutation in NFKB2 (c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-019-00602-xDOI Listing
March 2019
2 Reads

Treatment modalities of non-Hodgkin lymphoma patients over 65 years of age: A two-center experience.

J Oncol Pharm Pract 2019 Mar 29:1078155219839460. Epub 2019 Mar 29.

9 Department of Biostatistics and Medical Informatics, Bezmialem Vakif University, Istanbul, Turkey.

Objective: This study was conducted with the aim of making the contribution to a decision for treatment and determination of the modalities in patients diagnosed with non-Hodgkın lymphoma which increasingly become widespread in the geriatric population.

Materials And Methods: Ninety-one patients aged over 65 years diagnosed with lymphoma and treated in Bezmialem Vakıf University Medical Faculty Hospital and Haseki Training and Research Hospital between 2008 and 2013 were retrospectively evaluated. Finally, 63 patients for whom data could be reached were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219839460DOI Listing
March 2019
1 Read

Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.

Hematology 2019 Dec;24(1):413-419

a Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma , Peking University Cancer Hospital & Institute , Beijing , People's Republic of China.

Objectives: To analyze the clinical characteristics and prognosis of primary extranodal classical Hodgkin lymphoma (PE-cHL).

Methods: Clinical features and outcomes of 22 PE-cHL patients who received initial chemotherapy January 2008 to January 2018 were analyzed retrospectively, and compared with 274 primary nodal Hodgkin lymphoma (PN-cHL) patients treated in the same period.

Results: With a median follow-up period of 42 months, compared with 274 PN-cHL patients, no significant difference of overall response rate (ORR) or complete remission (CR) rate was found, but the PE-cHL patients showed a higher recurrence rate (36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2019.1598678DOI Listing
December 2019
1 Read

Palisaded Neutrophilic Granulomatous Dermatitis Leading to Diagnosis of Hodgkin Lymphoma: Report of Rare Case and Literature Review of Paraneoplastic Granulomatous Dermatitides.

Am J Dermatopathol 2019 Apr 1. Epub 2019 Apr 1.

Department of Dermatology, University of Wisconsin, Madison, WI.

Palisaded neutrophilic granulomatous dermatitis (PNGD) presents as skin-colored to erythematous papules symmetrically distributed on extensor extremities. Histologically, interstitial and/or palisaded granulomatous infiltrates are present with neutrophils and leukocytoclasis. Together with interstitial granulomatous dermatitis (IGD), PNGD is considered a reactive granulomatous dermatitis to a systemic trigger including connective tissue disease, infection, medication reaction, and less commonly malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001411DOI Listing
April 2019
1 Read

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.

J Cachexia Sarcopenia Muscle 2019 Feb;10(1):22-34

Division of Cardiology and Metabolism, Department of Cardiology & Berlin-Brandenburg Center for Regenerative Therapies (BCRT), DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Charité-Universitätsmedizin Berlin (CVK), Berlin, Germany.

Background: Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcsm.12402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438416PMC
February 2019
1 Read

Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.

Curr Oncol Rep 2019 Mar 27;21(5):39. Epub 2019 Mar 27.

Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Purpose Of Review: Availability of highly effective novel agents has altered the approach to initial therapy in patients with classical Hodgkin lymphoma (cHL). We will review controversies in the following areas: (1) the role of radiation in early unfavorable disease and the optimal treatment strategies for (2) advanced-stage disease and (3) elderly patients.

Recent Findings: Strategies incorporating brentuximab vedotin into frontline treatment of cHL yielded favorable results in non-randomized elderly studies and were compared to ABVD in advanced disease among adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0788-0DOI Listing
March 2019
1 Read

Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.

Hematol Oncol 2019 Mar 27. Epub 2019 Mar 27.

University of Connecticut/Hartford Hospital Evidence-based Practice Center, Hartford, Connecticut, United States of America.

Survival rates of patients with non-Hodgkin lymphoma (NHL) have improved over the last decade. However, cardiotoxicities remain important adverse consequences of treatment with chemotherapy and radiation, although the burden of cardiovascular mortality (CVM) in such patients remains unknown. We conducted a retrospective cohort study of patients greater than or equal to 20 years of age diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) between 2000 and 2013 using data extracted from the United States Surveillance, Epidemiology, and End Results (SEER) database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2607DOI Listing
March 2019
4 Reads

Evaluation of 22 Primary Gastrointestinal Lymphoma Patients.

Eurasian J Med 2019 Feb;51(1):53-56

Department of Medical Oncology, Atatürk University School of Medicine, Erzurum, Turkey.

Objective: Primary gastrointestinal non-hodgkin lymphomas (PGI-NHL) are uncommon diseases with treatment modalities including chemotherapy, surgery, and radiotherapy. Our aim is to analyze the demographic and clinical features and treatment results of PGI-NHL.

Materials And Methods: 286 patients diagnosed with lymphoma who referred to Ataturk University Medical Faculty Hospital between July 2001 and April 2014 were surveyed retrospectively and 22 (7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/eurasianjmed.2019.16071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422615PMC
February 2019
1 Read

A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment.

J Oncol Pharm Pract 2019 Mar 25:1078155219837331. Epub 2019 Mar 25.

2 Department of Pathology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Sarcoidosis is known to be associated with higher incidence of solid tumors and hematological malignancies. ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis. As this rare and highly mortal disease did not respond to classical chemotherapies and showed remission with brentuxumab vedontin treatment, we are presenting our first case reported from Turkey hoping to contribute to the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219837331DOI Listing
March 2019
1 Read

Global DNA methylation of peripheral blood leukocytes from dogs bearing multicentric non-Hodgkin lymphomas and healthy dogs: A comparative study.

PLoS One 2019 25;14(3):e0211898. Epub 2019 Mar 25.

Laboratory of Experimental and Comparative Oncology, Department of Pathology, University of São Paulo, São Paulo, São Paulo, Brazil.

Non-Hodgkin lymphomas are among the most common types of tumors in dogs, and they are currently accepted as comparative models of the disease in humans. Aberrant patterns of DNA methylation seem to play a key role in the development of hematopoietic neoplasms in humans, constitute a special mechanism of transcriptional control, and may be influenced by genetic and environmental factors. Blood leukocyte DNA global methylation has been poorly investigated in dogs. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211898PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433272PMC
March 2019
1 Read
3.234 Impact Factor

Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features.

J Neurol Sci 2019 Mar 14;400:34-38. Epub 2019 Mar 14.

Department of Neurology, Medical University of South Carolina, Charleston, SC, USA.

Objective: Primary central nervous system (CNS) lymphoma (PCNSL) is a rare, aggressive, yet highly chemosensitive form of non-Hodgkin lymphoma which is associated with significant morbidity. Very little is known about the long-term risk for and features of seizures associated with this condition.

Methods: We performed a retrospective and longitudinal analysis of 36 patients with pathologically and radiographically confirmed primary CNS lymphoma to evaluate the incidence, prevalence and features associated with seizures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.03.011DOI Listing
March 2019
2 Reads

Early evaluation of tumor response to Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?

Eur Radiol 2019 Mar 21. Epub 2019 Mar 21.

Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.

Purpose: To determine the earliest optimal timing for assessment of early response following radioimmunotherapy in non-Hodgkin lymphoma patients using FDG-PET/CT.

Methods: FDG-PET/CT was performed prior to treatment (PET1), at 2 (PET2) weeks, and at 6 (PET3) weeks after Y-ibritumomab radioimmunotherapy in 55 patients. Response was evaluated based on the Deauville 5-point scale and Lugano criteria as well as semiquantitative analysis and compared with progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06134-7DOI Listing
March 2019
1 Read

Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders.

Front Oncol 2019 7;9:109. Epub 2019 Mar 7.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, affecting up to 90% of the population. EBV was first identified as an oncogenic virus in a Burkitt lymphoma cell line, though subsequently has been found to drive a variety of malignancies, including diffuse large B-cell lymphoma (DLBCL) and other lymphoma subtypes. EBV has a tropism for B-lymphocytes and has the unique ability to exist in a latent state, evading the host immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416204PMC
March 2019
2 Reads

Primary adrenal Hodgkin lymphoma.

Clin Case Rep 2019 Mar 22;7(3):568-569. Epub 2019 Jan 22.

Department of Internal Medicine Hurley Medical Center Flint Michigan.

A 75-year-old man with a left adrenal mass found on CT scan showed Hodgkin disease on biopsy. Bone marrow biopsy was normal. This is the fourth case in the literature of primary adrenal Hodgkin lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406137PMC
March 2019
1 Read

A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016.

BMC Infect Dis 2019 Mar 21;19(1):274. Epub 2019 Mar 21.

Department of Infectious Diseases, Alfred Health and Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Background: Little is known about the morbidity and mortality of invasive fungal disease (IFD) at a population level. The aim of this study was to determine the incidence, trends and outcomes of IFD in all haematology-oncology patients by linking Victorian hospital data to state-based registries.

Methods: Episodes of IFD complicating adult haematological malignancy (HM) and haematopoietic stem cell transplantation (HSCT) patients admitted to Victorian hospitals from 1 July 2005 to 30 June 2016 were extracted from the Victorian Admitted Episodes Dataset and linked to the date of HM diagnosis from the Victorian Cancer Registry and mortality from the Victorian Death Index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-019-3901-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429824PMC
March 2019
2 Reads

Noncancer mortality among adolescents and young adults with cancer.

Cancer 2019 Mar 20. Epub 2019 Mar 20.

Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.

Background: Relative to the general population, cancer patients and survivors may have an elevated risk of mortality from noncancer causes, such as cardiovascular disease and infections, but few studies have examined rates of noncancer mortality among patients diagnosed as adolescents and young adults (AYAs) (ages 15-39 years).

Methods: The Surveillance, Epidemiology, and End Results database was used to identify AYA patients who were diagnosed with a first malignant cancer between 1973 and 2015. Rates of mortality from noncancer causes among AYAs with cancer were compared with those in the general US population using standardized mortality ratios (SMRs), adjusted for age, sex, race, and calendar year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32063DOI Listing
March 2019
1 Read

A possible case of Erdheim-Chester Disease.

Rom J Ophthalmol 2018 Oct-Dec;62(4):308-311

University Hospital in Château-Gontier, France.

To present the case of a 57-year-old male with progressive bilateral proptosis. The patient presented with bilateral proptosis and strength deficiency on the upper limbs. During hospitalization, the progression was unfavorable; proptosis progressed, causing a severe loss of vision in the left eye (from 0. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421492PMC

Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.

Nat Commun 2019 03 19;10(1):1252. Epub 2019 Mar 19.

Department of Medical and Clinical Genetics, University of Helsinki, FI-00014, Helsinki, Finland.

Clonal hematopoiesis driven by somatic heterozygous TET2 loss is linked to malignant degeneration via consequent aberrant DNA methylation, and possibly to cardiovascular disease via increased cytokine and chemokine expression as reported in mice. Here, we discover a germline TET2 mutation in a lymphoma family. We observe neither unusual predisposition to atherosclerosis nor abnormal pro-inflammatory cytokine or chemokine expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09198-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424975PMC
March 2019
8 Reads

Controversies in the Treatment of Classical Hodgkin Lymphoma.

Hemasphere 2018 Oct 2;2(5):e149. Epub 2018 Oct 2.

First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.

Hodgkin lymphoma (HL) is a B-cell-derived malignancy that mostly affects young adults. Pathologically, HL is divided into classical HL (cHL) and the rare entity of nodular lymphocyte-predominant HL. Classical HL is characterized by few malignant cells termed Hodgkin and Reed-Sternberg cells embedded in an inflammatory background. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407792PMC
October 2018
1 Read

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.

Front Oncol 2019 1;9:107. Epub 2019 Mar 1.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma worldwide, representing 30-40% of non-Hodgkin lymphomas, and is clinically aggressive. Although more than half of patients with DLBCL are cured by using standard first-line immunochemotherapy, the remaining patients are refractory to the first-line therapy or relapse after complete remission and these patients require novel therapeutic approaches. Understanding the pathogenesis of DLBCL is essential for identifying therapeutic targets to tackle this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406015PMC
March 2019
1 Read

The clinicopathologic features and response to treatment of patients with Nonhodgkin Lymphoma: A single-center experiment in Turkey.

Pak J Med Sci 2019 Jan-Feb;35(1):82-85

Dr. Gulden Sincan, Department of Hematology, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.

Objective: We aimed to compare laboratory features, histopathological types, response to treatment of patients with non hodgkin lymphoma in our department and other regions.

Methods: A total of 80 patients nonhodgkin lymphoma were evaluated. Because we had only 80 patients with complete data, we used T test for comparison of groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12669/pjms.35.1.415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408640PMC
March 2019
1 Read

Frequency and causes of anemia in Lymphoma patients.

Pak J Med Sci 2019 Jan-Feb;35(1):61-65

Dr. Neelam Siddiqui, MRCP, FRCP, CCST (Medical Oncology), Consultant Oncologist, Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.

Objective: Purpose of this study was to find out frequency of anemia and its causes in newly diagnosed treatment naive lymphoma patients.

Methods: We retrospectively studied all lymphoma patients (> 18 years age) diagnosed and treated at Shaukat Khanum Memorial Cancer Hospital and Research Centre, from January 2016 till January 2017. The data was collected from electronic Hospital Information System. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12669/pjms.35.1.91DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408630PMC
March 2019
3 Reads

Prospective comparative study of the effects of lidocaine on urodynamic and sensory parameters in bladder pain syndrome.

Int Urogynecol J 2019 Mar 14. Epub 2019 Mar 14.

Department of Urogynaecology, Cork University Maternity Hospital, Wilton, Co. Cork, Ireland.

Introduction And Hypothesis: Intravesically administered lidocaine is used in patients with bladder pain syndrome (BPS) to test the hypothesis that symptoms have a peripheral versus central mechanism.

Methods: A cross-sectional study of 24 female patients with BPS was performed. The Central Sensitisation Inventory (CSI) and Kings Health Questionnaire (KHQ) were completed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00192-019-03892-2DOI Listing
March 2019
4 Reads

Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.

Expert Rev Hematol 2019 Mar 15:1-10. Epub 2019 Mar 15.

d Case Comprehensive Cancer Center , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50-60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1593135DOI Listing
March 2019
4 Reads

Couples Dealing With Pediatric Blood Cancer: A Study on the Role of Dyadic Coping.

Front Psychol 2019 27;10:402. Epub 2019 Feb 27.

Department of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium.

Pediatric cancer is a life-threatening disease that poses significant challenges to the ill child and his/her parents. Among the studies investigating risk and protective factors for the individual and relationship adjustment of parents being confronted with pediatric cancer, couple factors - such as dyadic coping - gained little research attention. Therefore, the aim of the current study was to explore the association between dyadic coping and individual/relationship outcomes of parents in the context of pediatric cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fpsyg.2019.00402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400881PMC
February 2019
1 Read

Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.

Ann Hematol 2019 Mar 14. Epub 2019 Mar 14.

Haematology, "Policlinico" Hospital, Bari, Italy.

This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)-pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin's lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03662-6DOI Listing
March 2019
1 Read